Cyclopharm reports record half-year revenue on 74% U.S. growth
Cyclopharm said half-year revenue hit a record, driven by 74% U.S. growth and improved gross margins. Company also named Technegas as the preferred agent in new international guidelines.
Story updates
02:24:03 AM UTC
SquawkNews
Record half-year revenue up 14% to AUD 17.5 million, driven by 74% U.S. growth and margin expansion. New international guidelines name Technegas as preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.Based on Cyclopharm Limited [CYC] H1 2026 Audio Transcript…
Record half-year revenue up 14% to AUD 17.5 million, driven by 74% U.S. growth and margin expansion.
New international guidelines name Technegas as preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.Based on Cyclopharm Limited [CYC] H1 2026 Audio Transcript…